Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells

Hepatology

Volumn 42, Issue 4, 2005, Pages 871-879

  Wang, Guqi ^a   Gong, Yuewen ^a   Anderson, Judy ^a   Sun, Dongfeng ^a   Minuk, Gerald ^a   Roberts, Michael S ^b   Burczynski, Frank J ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FATTY ACID BINDING PROTEIN; FLUORESCENT DYE; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; LIVER FATTY ACID BINDING PROTEIN; LIVER PROTEIN; MESSENGER RNA; PLASMID DNA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CLONE; CELL HYPOXIA; CELL PROTECTION; CELL STRAIN; CHANG LIVER CELL; CONTROLLED STUDY; ENZYME RELEASE; EXPERIMENTAL MODEL; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PCDNA3.1; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; REOXYGENATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANOXIA; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FATTY ACID-BINDING PROTEINS; GLUTATHIONE; HEPATOCYTES; HUMANS; HYDROGEN PEROXIDE; LIVER NEOPLASMS; OXIDANTS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 25844523313     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20857     Document Type: Article

References (50)

1. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 1998;247:166-170.
2. Bordewick U, Heese M, Borchers T, Robenek H, Spener F. Compartmentation of hepatic fatty-acid-binding protein in liver cells and its effect on microsomal phosphatidic acid biosynthesis. Biol Chem Hoppe Seyler 1989;370:229-238.
3. Fahimi HD, Voelkl A, Vincent SH, Muller-Eberhard U. Localization of the heme-binding protein in the cytoplasm and of a heme-binding protein-like immunoreactive protein in the nucleus of rat liver parenchymal cells: immunocytochemical evidence of the subcellular distribution corroborated by radioimmunoassay and immunoblotting. HEPATOLOGY 1990;11: 859-865.
4. Ek-Von Mentzer BA, Zhang F, Hamilton JA. Binding of 13-hode and 15-hete to phospholipid bilayers, albumin, and intracellular fatty acid binding proteins, implications for transmembrane and intracellular transport and for protection from lipid peroxidation. J Biol Chem 2001;276: 15575-15580.
5. Raza H, Pongubala JR, Sorof S. Specific high affinity binding of lipoxygenase metabolites of arachidonic acid by liver fatty acid binding protein. Biochem Biophys Res Commun 1989;161:448-455.
6. Burnett DA, Lysenko N, Manning JA, Ockner RK. Utilization of long chain fatty acids by rat liver: studies of the role of fatty acid binding protein. Gastroenterology 1979;77:241-249.
7. Thompson J, Reese-Wagoner A, Banaszak L. Liver fatty acid binding protein: species variation and the accommodation of different ligands. Biochim Biophys Acta 1999;1441:117-130.
8. Bassuk JA, Tsichlis PN, Sorof S. Liver fatty acid binding protein is the mitosis-associated polypeptide target of a carcinogen in rat hepatocytes. Proc.Natl.Acad.Sci U S A 1987;84:7547-7551.
9. Wang G, Chen QM, Mimik GY, Gong Y, Burczynski FJ. Enhanced expression of cytosolic fatty acid binding protein and fatty acid uptake during liver regeneration in rats. Mol Cell Biochem 2004;262:41-49.
10. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovasc Toxicol 2002;2:111-118.
11. Wang G, Burczynski F, Hasinoff B, Zhong G. Infection of myocytes with chlamydiae. Microbiology 2002;148:3955-3959.
12. Subramaniam R, Fan XJ, Scivittaro V, Yang J, Ha CE, Petersen CE, et al. Cellular oxidant stress and advanced glycation endproducts of albumin: caveats of the dichlorofluorescein assay. Arch Biochem Biophys 2002;400: 15-25.
13. Jacschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Phiysiol Gastrointest Liver Physiol 2003;284: G15-G26.
14. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996;35:243-282.
15. Atshaves BP, Storey SM, Petrescu A, Greenberg CC, Lyuksyutova OI, Smith R III, et al. Expression of fatty acid binding proteins inhibits lipid accumulation and alters toxicity in L cell fibroblasts. Am J Physiol Cell Physiol 2002;283:C688-C703.
16. Huang H, Starodub O, McIntosh A, Atshaves BP, Woldegiorgis G, Kier AB, et al. Liver fatty acid-binding protein colocalizes with pcroxisome proliferator activated receptor alpha and enhances ligand distribution to nuclei of living cells. Biochemistry 2004;43:2484-2500.
17. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectromerty and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis 1999;20:2952-2960.
18. Guajardo MH, Terrasa AMC. Retinal fatty acid binding protein reduce lipid peroxidation stimulated by long-chain fatty acid hydroperoxides on rod outer segments. Biochim Biophys Acta 2002;158:65-74.
19. Ek BA, Cistola DP, Hamilton JA, Kaduce TL, Spector AA. Fatty acid binding proteins reduce 15-lipoxygenase-induced oxygenation of linoleic acid and arachidonic acid. Biochim Biophys Acta 1997;1346:75-85.
20. Catala A, Cerruti A, Arcemis C. Inhibition of microsomal chemiluminescence by cytosolic fractions containing tatty acid binding protein. Arch Physiol Biochem 1995;103:39-43.
21. Samaina A, Das DK, Jones R, George A, Prasad MR. Free radical scavenging by myocardial fatty acid binding protein. Free Radic Res Commun 1989;7:73-82.
22. Zimmerman AW, Veerkamp JH. Fatty-acid-binding proteins do not protect against induced cytotoxicity in a kidney cell model. Biochem J 2001; 360:159-165.
23. Halliwell B. Antioxidant defense mechanisms: from the beginning to the end (of the Beginning). Free Radic Res 1999;31:261-272.
24. Csonka C, Pataki T, Kovacs P, Muller SL, Schroeter ML, Tosaki A, et al. Effects of oxidative stress on the expression of antioxidative defense enzymes in spontaneously hypertensive rat hearts. Free Radic Biol Med 2000; 29:612-619.
25. Khynriam D, Prasad SB. Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. Cell Biol 1 Toxicol 2002;18: 349-358.
26. Matsumaru K, Ji C, Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. HEPATOLOGY 2003;37:1425-1434.
27. Okuyama H, Nakamura H, Shimahara Y, Araya S, Kawada N, Yamaoka Y, et al. Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. HEPATOLOGY 2003;37:1015-1025.
28. Moskovitz J, Jenkins NA, Gilbert DJ, Copeland NG, Jursky F, Weissbach H, et al. Chromosoinal localization of the mammalian peptide-methionine sulfoxide reductase gene and its differential expression in various tissues. Proc Natl Acad Sci U S A 1996;93:3205-3208.
29. Levine RL, Berlett BS, Moskovitz J, Mosoni L, Stadtman ER. Methionine residues may protect proteins from critical oxidative damage. Mech Ageing Dev 1999;107:323-332.
30. Moskoviiz I, Berlett BS, Poston JM, Stadtman ER. Methioninc sulfoxide reductase in antioxidant defense. Methods Enzymol 1999;300:239-244.
31. Levine RL, Mosoni L, Berlett BS, Stadtman ER. Methionine residues as endogenous antioxidants in proteins. Proc Natl Acad Sci U S A 1996;93: 15036-15040.
32. Stadtman ER. Cyclic oxidation and reduction of methionine residues of proteins in antioxidant defense and cellular regulation. Arch Biochem Biophys 2004;423:2-5.
33. Thomas JA, Poland B, Honzatko R. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch Biochem Biophys 1995;319:1-9.
34. Sato T, Baba K, Takahashi Y, Uchiumi T, Odani S. Rat liver fatty acid-binding protein: identification of a molecular species having a mixed disulfide with cysteine at cysteine-69 and enhanced protease susceptibility. J Biochem 1996;120:908-914.
35. Bernlohr DA, Simpson MA, Hertzel AV, Banaszak LJ. Intracellular lipid-binding proteins and their genes. Annu Rev Nutr 1997;17:277-303.
36. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 1993;31:857-907.
37. Goel SK, Lalwani ND, Reddy JK. Peroxisome prolileration and lipid peroxidation in rat liver. Cancer Res 1986;46:1324-1330.
38. Tamura H, Iida T, Watanabe T, Suga T. Long-term effects of hypolipidemic peroxisome prolifevaror administration on hepatic hydrogen peroxide metabolism in rats. Carcinogenesis 1990;11:445-450.
39. Reddy JK, Rao MS. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat Res 1989;214: 63-68.
40. Tomaszewski KE, Aganval DK, Melnick KL. In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. Carcinogenesis 1986;7:1871-1876.
41. Perera MI, Katyal SL, Shinozuka U. Suppression of choline-deficient diet-induced hepatocyte membrane lipid peroxidation in rats by tbe peroxisome proliferators 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio(N-beta-hydroxyethyl)- acetamide and di(2-ethylbexyl)phthalate. Cancer Res 1986;46:3304-3308.
42. Elliott BM, Elcombe CR. Lack of DNA damage or lipid peroxidation measured in vivo in the rat liver following treatment with peroxisomal proliferators. Carcinogenesis 1987;8:1213-1218.
43. Handler JA, Seed CB, Bradford BU, Thurman RG. Induction of peroxisomes by treatment with perfluorooctanoate does not increase rates of H2O2 production in intact liver. Toxicol Lett 1992;60:61-68.
44. Conway JG, Popp JA. Effect of the hepatocarcinogemic peroxisome proliferator Wy-14.643 in vivo: no increase in ethane exhalation or hepatic conjugated dienes. Toxicol Appl Pharmacol 1995;135:229-236.
45. Garberg P, Stenins U, Nilsson K, Hogberg J. Peroxisome proliferation and resistance to hydrogen peroxide in rat hepatocytes: is development of resistance an adaptation 10 cytotoxicity? Carcinogenesis 1992;13:1751-1758.
46. Deplanque D. [Cell protection through PPAR nuclear receptor activation]. Therapie 2004;59:25-29.
47. Tuchweber B, Salas M. Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds. Arch Toxicol 1978;41:223-232.
48. Chen C, Hennig GE, Whiteley HIC, Manautou JL. Protection against acetaminophen hepatotoxicity by clofibrate pretreatment: role of catalase induction. J Biochem Mol Toxicol 2002;16:227-234.
49. Nicholls-Grzemski PA, Calder IC, Priestly BG, Burcham PC. Clofibrate-indueed in vitro hepatoprotection against acetaminophen is not due to altered glutathione homeostasis. Toxicol Sci 2000;56:220-228.
50. Nicholls-Grzemski FA, Belling CB, Priestly BG, Calder IC, Burcham PC. Clohbrate pretreatment in mice confers resistance against hepatic lipid peroxidation. J Biochem Mol Toxicol 2000;14:335-345.